The Presence of Antiphospholipid Antibodies in Healthy <scp>B</scp>ernese <scp>M</scp>ountain <scp>D</scp>ogs

Nielsen, Lise Nikolic; Wiinberg, Bo; Kjelgaard‐Hansen, Mads; Kristensen, Annemarie T.

doi:10.1111/j.1939-1676.2011.00823.x

Cited by 7 publications

(4 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the 4 dogs for which data are available, the PTT elevations appear within the first 1-7 days after administration of virus and were persistent at 3-and 9-month follow-up examinations in 1/4 and 2/4 dogs, respectively. This phenomenon has been documented to occur in dogs with noninfectious diseases and in a subset of healthy Bernese Mountain Dogs (Nielsen et al, 2011). PTT elevations were seen transiently in rats receiving 10 9 TCID 50 of VSV-hIFNb virus intrahepatically, but the direct administration of virus into the liver could directly interfere with coagulation factor production in this organ.…”

Section: Safety Studies Of Oncolytic Vsv In Dogsmentioning

confidence: 95%

Safety Studies on Intravenous Administration of Oncolytic Recombinant Vesicular Stomatitis Virus in Purpose-Bred Beagle Dogs

LeBlanc

Naik

Galyon

et al. 2013

Human Gene Therapy Clinical Development

View full text Add to dashboard Cite

VSV-IFNβ-NIS is a novel recombinant oncolytic vesicular stomatitis virus (VSV) with documented efficacy and safety in preclinical murine models of cancer. To facilitate clinical translation of this promising oncolytic therapy in patients with disseminated cancer, we are utilizing a comparative oncology approach to gather data describing the safety and efficacy of systemic VSV-IFNβ-NIS administration in dogs with naturally occurring cancer. In support of this, we executed a dose-escalation study in purpose-bred dogs to determine the maximum tolerated dose (MTD) of systemic VSV-hIFNβ-NIS, characterize the adverse event profile, and describe routes and duration of viral shedding in healthy, immune-competent dogs. The data indicate that an intravenous dose of 10(10) TCID50 is well tolerated in dogs. Expected adverse events were mild to moderate fever, self-limiting nausea and vomiting, lymphopenia, and oral mucosal lesions. Unexpected adverse events included prolongation of partial thromboplastin time, development of bacterial urinary tract infection, and scrotal dermatitis, and in one dog receiving 10(11) TCID50 (10 × the MTD), the development of severe hepatotoxicity and symptoms of shock leading to euthanasia. Viral shedding data indicate that detectable viral genome in blood diminishes rapidly with anti-VSV neutralizing antibodies detectable in blood as early as day 5 postintravenous virus administration. While low levels of viral genome copies were detectable in plasma, urine, and buccal swabs of dogs treated at the MTD, no infectious virus was detectable in plasma, urine, or buccal swabs at any of the doses tested. These studies confirm that VSV can be safely administered systemically in dogs, justifying the use of oncolytic VSV as a novel therapy for the treatment of canine cancer.

show abstract

Section: Safety Studies Of Oncolytic Vsv In Dogsmentioning

confidence: 95%

Safety Studies on Intravenous Administration of Oncolytic Recombinant Vesicular Stomatitis Virus in Purpose-Bred Beagle Dogs

LeBlanc

Naik

Galyon

et al. 2013

Human Gene Therapy Clinical Development

View full text Add to dashboard Cite

show abstract

“…Samples were thawed in a water bath for 4 min at 37 °C and then thoroughly mixed [ 49 ]. A platelet count below 10 × 10 9 /L [ 50 ] in the PPP was ensured by platelet measurement prior to hemostatic analysis (ADVIA 2120i, Siemens Healthcare A/S, Ballerup, Denmark).…”

Section: Methodsmentioning

confidence: 99%

A pilot study evaluating the Calibrated Automated Thrombogram assay and application of plasma-thromboelastography for detection of hemostatic aberrations in horses with gastrointestinal disease

2021

View full text Add to dashboard Cite

Background Critically ill horses, such as horses with gastrointestinal (GI) disease, often suffer from hemostatic aberrations. Global hemostatic tests examining the initiation of coagulation, clot strength and fibrinolysis, such as the Calibrated Automated Thrombogram (CAT) and plasma-thromboelastography (TEG) have not been evaluated in horses. This study aimed to evaluate CAT and apply plasma-TEG in horses. Test performance of CAT was evaluated on equine platelet poor plasma with intra- and inter-assay variability (CV) and a heparin dilution curve. To examine clinical performance of both tests, group comparisons were assessed comparing healthy horses, horses with mild and severe GI disease with both CAT and plasma-TEG. Results For CAT, intra- and inter-assay CVs were established for lag-time (1.7, 4.7%), endogenous thrombin potential (1.6, 4.6%), peak (2.6, 3.9%) and time to peak (ttPeak) (1.9, 3.4%). Increasing heparin concentrations led to the expected decrease in thrombin generation. In the group comparison analysis, CAT showed significant higher peak (p = 0.04) and ttPeak (p = 0.008) in the severe GI disease group compared to horses with mild GI disease and healthy horses, respectively. Plasma-TEG showed an increased angle (p = 0.032), maximum amplitude (p = 0.017) and shear elastic force (G) (p = 0.017) in the severe GI disease group compared to healthy horses. Conclusions CAT performed well in horses. Both CAT and plasma-TEG identified hemostatic aberrations in horses with severe GI disease compared to healthy horses. Further studies including more horses, are needed to fully appreciate the use of CAT and plasma-TEG in this species.

show abstract

“…The equivocal results of these tests could be related to the wide range of different analyses offered commercially, which include different concentrations and compositions. The tests can be performed on either citrate-stabilized whole blood or plasma, can be analyzed in smaller table-size instruments as well as in larger reference laboratories, and, within the test set-up, can be initiated by a range of different activating agents, which ultimately will affect the analytical sensitivity and specificity for detection of bleeding [74,[81][82][83]. However, it is also possible that coagulation factors are unaffected in some bleeding dogs with angiostrongylosis.…”

Section: Coagulation Factor Analysesmentioning

confidence: 99%

Hemostatic Dysfunction in Dogs Naturally Infected with Angiostrongylus vasorum—A Narrative Review

2022

View full text Add to dashboard Cite

This narrative review aims to describe Angiostrongylus vasorum-induced hemostatic dysfunction of dogs with emphasis on clinical and laboratory findings as well as potential therapeutic strategies for the bleeding patient. Canine angiostrongylosis (CA) is a disease with potentially high morbidity and mortality in endemic areas and with fatal outcome often associated with either severe respiratory compromise, pulmonary hypertension and right-sided heart failure, or hemostatic dysfunction with severe bleeding. The most common signs of hemorrhage are hematomas, petecchiation, ecchymoses, oral mucosal membrane bleeding and scleral bleeding, while intracranial and pulmonary hemorrhage are among the most severe. The pathophysiological mechanisms underlying hemostatic dysfunction in these patients are presently researched. While the larval effect on platelets remains unknown, the parasite appears to induce dysregulation of hemostatic proteins, with studies suggesting a mixture of pro-coagulant protein consumption and hyperfibrinolysis. Importantly, not all dogs display the same hemostatic abnormalities. Consequently, characterizing the hemostatic state of the individual patient is necessary, but has proven difficult with traditional coagulation tests. Global viscoelastic testing shows promise, but has limited availability in general practice. Treatment of A. vasorum-infected dogs with hemostatic dysfunction relies on anthelmintic treatment as well as therapy directed at the individual dog’s specific hemostatic alterations.

show abstract

The Presence of Antiphospholipid Antibodies in Healthy Bernese Mountain Dogs

Cited by 7 publications

References 36 publications

Safety Studies on Intravenous Administration of Oncolytic Recombinant Vesicular Stomatitis Virus in Purpose-Bred Beagle Dogs

Safety Studies on Intravenous Administration of Oncolytic Recombinant Vesicular Stomatitis Virus in Purpose-Bred Beagle Dogs

A pilot study evaluating the Calibrated Automated Thrombogram assay and application of plasma-thromboelastography for detection of hemostatic aberrations in horses with gastrointestinal disease

Hemostatic Dysfunction in Dogs Naturally Infected with Angiostrongylus vasorum—A Narrative Review

Contact Info

Product

Resources

About